What is Biological E?
Biological E. Ltd. (BE) stands as a prominent vaccine and pharmaceutical manufacturer, deeply integrated into India's public health infrastructure. Established in 1953 and headquartered in Telangana, India, the company is a key supplier for the National Immunization Program. Its operations encompass the production of a diverse portfolio of essential vaccines, positioning it as a critical player in both domestic and potentially global health initiatives.
How much funding has Biological E raised?
Biological E has raised a total of $5M across 1 funding round:
Grant
$5M
Grant (2020): $5M with participation from Coalition for Epidemic Preparedness Innovations
Key Investors in Biological E
Coalition for Epidemic Preparedness Innovations
The Coalition for Epidemic Preparedness Innovations (CEPI) is a global partnership focused on funding and coordinating the development of vaccines against emerging infectious diseases. Their investment in Biological E. highlights a shared commitment to advancing vaccine technology and global health security.
What's next for Biological E?
The recent major strategic investment into Biological E. signals a phase of accelerated growth and expanded operational capacity. This capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and potentially broaden the company's market reach. As an established entity with a long history of contributing to public health, this financing round suggests a strategic push towards scaling its impact and solidifying its position as a leader in vaccine production.
See full Biological E company page
